Arizona State Retirement System Purchases New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Arizona State Retirement System purchased a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 6,693 shares of the biotechnology company’s stock, valued at approximately $211,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ARCT. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Arcturus Therapeutics by 5.9% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 606 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in Arcturus Therapeutics by 29.9% during the first quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 616 shares in the last quarter. Rhumbline Advisers boosted its stake in Arcturus Therapeutics by 1.9% during the third quarter. Rhumbline Advisers now owns 36,437 shares of the biotechnology company’s stock worth $931,000 after acquiring an additional 675 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Arcturus Therapeutics by 7.9% during the second quarter. The Manufacturers Life Insurance Company now owns 9,258 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 681 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Arcturus Therapeutics by 1.4% during the second quarter. Swiss National Bank now owns 52,100 shares of the biotechnology company’s stock worth $1,494,000 after acquiring an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Down 1.3 %

Shares of ARCT stock opened at $25.98 on Monday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $43.81. The firm’s 50 day moving average is $34.92 and its 200 day moving average is $29.80. The stock has a market capitalization of $699.38 million, a P/E ratio of -24.98 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. The company had revenue of $33.99 million for the quarter, compared to analysts’ expectations of $64.14 million. As a group, equities analysts predict that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 8,565 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.01, for a total value of $299,860.65. Following the sale, the chief operating officer now owns 490,883 shares in the company, valued at $17,185,813.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 13.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ARCT. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. Citigroup increased their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.33.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.